AbbVie Inc.
ABBVNYSE · SIC 2834
$254.49
↑ +0.0%Jul 17 close · end-of-day
Price
1Y↑ +37.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$451.5B
Enterprise Value
$514.9B
P/E
125.4
P/S
7.2
P/B
—
EV/EBITDA
32.0
PEG
—
FCF Yield
4.4%
Dividend Yield
2.6%
Revenue (TTM)
$62.8B
Net Income (TTM)
$3.6B
Free Cash Flow (TTM)
$20.0B
Gross Margin
—
Operating Margin
24.4%
Net Margin
5.8%
ROE
-54.6%
ROIC
16.4%
Debt / Equity
-10.9
Net Cash
-$63.5B
Return 1Y
+37.1%
Company profile
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.
- CEO
- Richard A. Gonzalez
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50,000
- Headquarters
- Illinois
- Website
- abbvie.com
Management & directors
- Purdue David RyanSVP, Controller
- Siatis Perry CEVP, GC AND SECRETARY
- Crum Demetris DEVP, CHIEF HR OFFICER
- Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER
- Michael Robert A.CHAIRMAN OF THE BOARD AND CEO
- Reents Scott TEVP, CHIEF FINANCIAL OFFICER
- Saleki-Gerhardt AzitaEVP, CHIEF OPERATIONS OFFICER
- Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER
- Thakkar RoopalEVP, R&D and CSO
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-10-05
ABBV Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$15.0B↑ +12.4%
Diluted EPS$0.39↓ -45.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $45.8B | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $11.4B | $17.9B | $18.1B | $12.8B | $9.1B | $15.1B |
| Net income | $4.6B | $11.5B | $11.8B | $4.9B | $4.3B | $4.2B |
| Diluted EPS | $2.72 | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
| Operating cash flow | $17.6B | $22.8B | $24.9B | $22.8B | $18.8B | $19.0B |
| Free cash flow | $16.8B | $22.0B | $24.2B | $22.1B | $17.8B | $17.8B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 24.8% | 31.9% | 31.2% | 23.5% | 16.2% | 24.6% |
| Net margin | 10.1% | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.5B | $14.5B | $15.1B | $13.3B | $15.4B | $15.8B | $16.6B | $15.0B |
| Gross profit | — | — | $10.7B | — | — | — | $12.1B | — |
| Operating income | $4.0B | $3.8B | -$1.5B | $3.7B | $4.9B | $1.9B | $4.5B | $4.0B |
| Net income | $1.4B | $1.6B | -$22.0M | $1.3B | $938.0M | $186.0M | $1.8B | $695.0M |
| Diluted EPS | $0.77 | $0.88 | -$0.02 | $0.72 | $0.52 | $0.10 | $1.02 | $0.39 |
| Operating cash flow | $2.3B | $5.4B | $7.0B | $1.6B | $5.2B | $7.0B | $5.2B | $3.8B |
| Free cash flow | $2.0B | $5.2B | $6.8B | $1.4B | $4.9B | $6.6B | $4.9B | $3.6B |
| Gross margin | — | — | 70.9% | — | — | — | 72.6% | — |
| Operating margin | 27.6% | 26.5% | -9.9% | 28.0% | 31.7% | 12.1% | 27.3% | 26.6% |
| Net margin | 9.5% | 10.8% | -0.1% | 9.6% | 6.1% | 1.2% | 10.9% | 4.6% |
Company news
Jul 20, 2026
- 1h agoReading Between The Lines Of JNJ Stock's Latest Calltrefis.com
- 2h agoEli Lilly Stock And The Price Of Confidencetrefis.com
- 14h agoWhat Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.finance.yahoo.com
- 19h agoHow Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?fool.com
Jul 19, 2026
Jul 17, 2026
- 2d agoThe Real Question Buried Inside Merck Stock's Premium Pricetrefis.com
- 3d agoAbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In Europefinance.yahoo.com
- 3d agoVYM’s $94.6 Billion Portfolio Beats Treasury Yields with Dividend Kings Leading the Way247wallst.com
- 3d agoAllergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patientsfinance.yahoo.com
Jul 16, 2026
- 3d agoWhy Healthcare Stocks Look Like a Haven in This Marketfinance.yahoo.com
- 4d agoWhy Abbott Stock Is Having Its Best Day in 24 Yearsfinance.yahoo.com
- 4d agoWill AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?finance.yahoo.com
- 4d agoWhat Could Push LLY Stock Higher From Here?trefis.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-08 | FALK THOMAS J | Award | 1,118 | $0.00 | $0.00 | filing |
| 2026-05-08 | WADDELL FREDERICK H | Award | 1,118 | $0.00 | $0.00 | filing |
| 2026-05-08 | Roberts Rebecca B | Award | 1,118 | $0.00 | $0.00 | filing |
| 2026-05-08 | RAPP EDWARD J | Award | 1,118 | $0.00 | $0.00 | filing |
| 2026-05-08 | Quaggin Susan E | Award | 1,118 | $0.00 | $0.00 | filing |
| 2026-05-08 | MEYER MELODY B | Award | 1,118 | $0.00 | $0.00 | filing |
| 2026-05-08 | Hart Brett J | Award | 1,118 | $0.00 | $0.00 | filing |
| 2026-05-08 | FREYMAN THOMAS C | Award | 1,118 | $0.00 | $0.00 | filing |
| 2026-05-08 | Davis Jennifer L. | Award | 1,118 | $0.00 | $0.00 | filing |
| 2026-05-08 | BURNSIDE WILLIAM H.L. | Award | 1,118 | $0.00 | $0.00 | filing |
| 2026-05-08 | AUSTIN ROXANNE S | Award | 1,118 | $0.00 | $0.00 | filing |
| 2026-03-04 | Purdue David Ryan· SVP, Controller | Sale | 5,230 | $233.56 | $1.2M | filing |
| 2026-03-02 | Siatis Perry C· EVP, GC AND SECRETARY | Sale | 10,291 | $234.66 | $2.4M | filing |
| 2026-03-02 | Siatis Perry C· EVP, GC AND SECRETARY | Sale | 5,777 | $233.51 | $1.3M | filing |
| 2026-03-02 | Siatis Perry C· EVP, GC AND SECRETARY | Sale | 2,600 | $235.26 | $611,676.00 | filing |
| 2026-02-27 | Michael Robert A.· CHAIRMAN OF THE BOARD AND CEO | Tax withholding | 36,523 | $232.08 | $8.5M | filing |
| 2026-02-27 | Stewart Jeffrey Ryan· EVP, CHIEF COMMERCIAL OFFICER | Tax withholding | 23,812 | $232.08 | $5.5M | filing |
| 2026-02-27 | Reents Scott T· EVP, CHIEF FINANCIAL OFFICER | Tax withholding | 21,638 | $232.08 | $5.0M | filing |
| 2026-02-27 | SALEKI-GERHARDT AZITA· EVP, CHIEF OPERATIONS OFFICER | Tax withholding | 16,309 | $232.08 | $3.8M | filing |
| 2026-02-27 | Siatis Perry C· EVP, GC AND SECRETARY | Tax withholding | 14,850 | $232.08 | $3.4M | filing |
| 2026-02-27 | Donoghoe Nicholas· EVP, CHIEF BUS/STRAT OFFICER | Tax withholding | 12,874 | $232.08 | $3.0M | filing |
| 2026-02-27 | Thakkar Roopal· EVP, R&D and CSO | Tax withholding | 8,037 | $232.08 | $1.9M | filing |
| 2026-02-27 | Purdue David Ryan· SVP, Controller | Tax withholding | 2,692 | $232.08 | $624,759.36 | filing |
| 2026-02-27 | Purdue David Ryan· SVP, Controller | Tax withholding | 2,108 | $232.08 | $489,224.64 | filing |
| 2026-02-27 | Crum Demetris D· EVP, CHIEF HR OFFICER | Tax withholding | 1,594 | $232.08 | $369,935.52 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.